title: Ethical issues involved in establishing a registry for familial Alzheimer's disease.
abstract: In January 1992, the IMAGE Project extended the establishment of its registry of familial Alzheimer cases to all areas of the province of Quebec, for collection of epidemiological and clinical data, as well as biological samples. The aim is to study genetic transmission patterns of Alzheimer's disease (AD) and to provide a sampling framework for further etiologic and risk factor studies. The IMAGE registry already includes data of a population-based study in the Saguenay-Lac-St-Jean area; the project to collect data on familial AD (FAD) cases across the province of Quebec is known as the ALGENE Initiative. The registry is thus a collection of "AD families" for both familial and sporadic cases. The establishment of the registry involves several steps in the field work: recruitment and selection of families; collection of information on family medical history; selection of informative families and genetic testing for AD/FAD by linkage analysis. As AD is not homogeneous in its etiology and since we do not know if, in the event that genetics is involved in AD whether or not penetrance of the gene(s) is high, we must be aware of the "genetic horizons" of AD in collecting and conserving data on families of cases, and in the genetic testing for AD/FAD by linkage analysis. Families who choose genetic testing must be aware of the implications of our undertaking, assured of the confidentiality of the test and, at the same time, they must understand its limitations. The experimental nature of our research project raises ethical dilemmas. This article examines these initial considerations of the field work involved in developing a registry pertaining to genetic testing for AD/FAD by linkage analysis and offers some preliminary observations on the experience of the first year of this project.
authors.affiliation: Unité Interdisciplinaire du Projet IMAGE, Centre Hospitalier Côtes-des-Neiges, Montréal, Québec, Canada.
authors.forename: B
authors.initials: B
authors.lastname: Godard
authors.forename: B M
authors.initials: BM
authors.lastname: Knoppers
authors.forename: K
authors.initials: K
authors.lastname: Glass
authors.forename: M
authors.initials: M
authors.lastname: Grenon
authors.forename: R
authors.initials: R
authors.lastname: Bouchard
authors.forename: M
authors.initials: M
authors.lastname: Bouvier
authors.forename: J
authors.initials: J
authors.lastname: Goulet
authors.forename: D
authors.initials: D
authors.lastname: Gauvreau
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000235:genetics*; D032781:Codes of Ethics; D032962:Consent Forms; D030561:Databases, Nucleic Acid; D030881:Disclosure; D004992:Ethics, Medical; D015723:Gene Library; D006580:Genetic Carrier Screening; D005817:Genetic Counseling; D008040:Genetic Linkage / Q000235:genetics; D030661:Genetic Privacy; D036281:Genetic Research; D005820:Genetic Testing; D006801:Humans; D018579:Patient Selection; D026684:Personal Autonomy; D011792:Quebec; D012042:Registries; D035842:Research Subjects; D035844:Researcher-Subject Relations; D018570:Risk Assessment; D012307:Risk Factors